Report of Foreign Issuer (6-k)
September 20 2018 - 4:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2018
Commission File Number 001-37381
MEDIGUS
LTD.
(Translation of registrant’s name into English)
Omer
Industrial Park, No. 7A, P.O. Box 3030, Omer 8496500, Israel
(Address of principal
executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F
x
Form 40-F
Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __
Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __
EXPLANATORY NOTE
On September 20, 2018,
Medigus Ltd., or the Company, held an annual general meeting of its shareholders, or the Meeting, at the offices of Meitar Liquornik
Geva Leshem Tal Law Offices at 16 Abba Hillel Silver Rd., Ramat Gan, Israel. At the Meeting, shareholders voted on the
proposals detailed in the Company’s proxy statement for the Meeting that was attached as Exhibit 99.1 to a Report of Foreign
Private Issuer on Form 6-K that the Company furnished to the Securities and Exchange Commission on August 16, 2018.
At the Meeting, Proposals
Nos. 4 and 5 were approved and Proposals Nos. 1, 2 and 3 were not approved by the requisite vote of the Company’s shareholders.
Effective as of the end of the Meeting, the Company’s board of directors is comprised of four members, consisting of Prof.
Benad Goldwasser, Mr. Ronen Rosenbloom, Mr. Eli Yoresh and Mr. Eli Cohen.
This Form 6-K, is
incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-213280) and Form S-8 (File
No. 333-206803 and No. 333-221019).
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
MEDIGUS LTD.
|
|
|
|
Date: September 20, 2018
|
By:
|
/s/ Oded Yatzkan
|
|
|
Oded Yatzkan
|
|
|
Chief Financial Officer
|
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Apr 2023 to Apr 2024